Amplifications at these loci have been previously associated with aggressive and drug‐resistant cancers and included several oncogenes such as MYC, CCND1, and multiple fibroblast growth factors (Lundgren et al, 2008; Baslan et al, 2020). The gene discussed is MYC; the disease is cancer.